129 related articles for article (PubMed ID: 38823631)
41. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Gao B; Yang F; Zheng D; Hu S; Liu J; Liu H; Liu Y; Liu L; Wang R; Zhao Y; Cui C; Fang C; Yang J; Su S; Han Y; Yang X; Li B
J Hepatocell Carcinoma; 2023; 10():2265-2276. PubMed ID: 38107541
[TBL] [Abstract][Full Text] [Related]
42. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
[TBL] [Abstract][Full Text] [Related]
43. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.
Liao Y; Wang B; Huang ZL; Shi M; Yu XJ; Zheng L; Li S; Li L
PLoS One; 2013; 8(4):e60444. PubMed ID: 23565248
[TBL] [Abstract][Full Text] [Related]
44. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.
Liu J; Wang P; Shang L; Zhang Z; Tian Y; Chen X; Ma Y; Shao H
Hepatol Int; 2024 Apr; 18(2):595-609. PubMed ID: 37843788
[TBL] [Abstract][Full Text] [Related]
45. Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Li SQ; Wu JY; Wu JY; Xie H; Li JH; Zeng ZX; Fu YK; Liu DY; Li H; Chen WZ; Huang JY; Yan ML
J Hepatocell Carcinoma; 2023; 10():1799-1811. PubMed ID: 37850080
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis.
Yang XG; Sun YY; Wang HQ; Li DS; Xu GH; Huang XQ
Front Oncol; 2022; 12():914385. PubMed ID: 36176392
[TBL] [Abstract][Full Text] [Related]
47. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract][Full Text] [Related]
48. The alterations in peripheral lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in hepatocellular carcinoma.
Xie Q; Hu C; Luo C
J Cancer; 2023; 14(15):2946-2955. PubMed ID: 37781071
[No Abstract] [Full Text] [Related]
49. Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis.
Du C; Wu H; Zhong T; Zhai Q; Yuan J; Peng J; Ma R; Li J
Discov Oncol; 2024 May; 15(1):164. PubMed ID: 38744743
[TBL] [Abstract][Full Text] [Related]
50. The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma.
Lee SW; Yang SS; Lien HC; Peng YC; Tung CF; Lee TY
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013120
[TBL] [Abstract][Full Text] [Related]
51. [Clinical features and prognostic analysis of transarterial chemoembolization combined with targeted immunotherapy in the treatment of patients with hepatitis B virus-related intermediate-and advanced-stage hepatocellular carcinoma with secondary cholestasis].
Wang NN; Shen JM; Li HL; Wang X; Yang GD; Pan XC; Li J
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1149-1155. PubMed ID: 38238947
[No Abstract] [Full Text] [Related]
52. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study.
Zheng L; Fang S; Wu F; Chen W; Chen M; Weng Q; Wu X; Song J; Zhao Z; Ji J
Front Mol Biosci; 2020; 7():609322. PubMed ID: 33521054
[No Abstract] [Full Text] [Related]
53. TREM2
Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
[TBL] [Abstract][Full Text] [Related]
54. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
55. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
Li X; Ding X; Li W; Chen J
Cancer Immunol Immunother; 2023 Jun; 72(6):1395-1403. PubMed ID: 36441192
[TBL] [Abstract][Full Text] [Related]
56. The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC.
Sun T; Ren Y; Sun B; Chen L; Zhu L; Zhang L; Zheng C
J Hepatocell Carcinoma; 2023; 10():447-457. PubMed ID: 36960308
[TBL] [Abstract][Full Text] [Related]
57. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.
Marinelli B; Kim E; D'Alessio A; Cedillo M; Sinha I; Debnath N; Kudo M; Nishida N; Saeed A; Hildebrand H; Kaseb AO; Abugabal YI; Pillai A; Huang YH; Khan U; Muzaffar M; Naqash AR; Patel R; Fischman A; Bishay V; Bettinger D; Sung M; Ang C; Schwartz M; Pinato DJ; Marron T
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710293
[TBL] [Abstract][Full Text] [Related]
58. Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma.
Zhang JX; Chen P; Liu S; Zu QQ; Shi HB; Zhou CG
J Hepatocell Carcinoma; 2022; 9():265-272. PubMed ID: 35388358
[TBL] [Abstract][Full Text] [Related]
59. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
60. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
